ImmuCell (NASDAQ:ICCC) Releases Earnings Results, Beats Estimates By $0.15 EPS

ImmuCell (NASDAQ:ICCC) released its quarterly earnings results on Thursday. The biotechnology company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.05 by $0.15, FiscalAI reports. The firm had revenue of $7.19 million during the quarter, compared to the consensus estimate of $5.40 million. ImmuCell had a negative net margin of 1.82% and a negative return on equity of 1.88%.

ImmuCell Stock Performance

Shares of NASDAQ:ICCC traded down $0.08 during trading on Thursday, reaching $10.90. The company had a trading volume of 44,696 shares, compared to its average volume of 19,907. The firm has a market capitalization of $98.64 million, a price-to-earnings ratio of -181.64 and a beta of 0.54. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.82 and a quick ratio of 2.60. The stock’s fifty day moving average price is $10.50 and its 200 day moving average price is $8.50. ImmuCell has a fifty-two week low of $4.52 and a fifty-two week high of $12.10.

Insider Activity at ImmuCell

In related news, CEO Boekhorst Paul Francis Oliv Te purchased 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The stock was purchased at an average cost of $9.49 per share, with a total value of $75,920.00. Following the completion of the acquisition, the chief executive officer directly owned 17,785 shares in the company, valued at $168,779.65. This trade represents a 81.76% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 5.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On ImmuCell

A hedge fund recently raised its position in ImmuCell stock. Geode Capital Management LLC raised its position in ImmuCell Corporation (NASDAQ:ICCC) by 4.2% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 71,852 shares of the biotechnology company’s stock after acquiring an additional 2,907 shares during the period. Geode Capital Management LLC owned approximately 0.79% of ImmuCell worth $500,000 at the end of the most recent reporting period. 13.47% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ICCC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ImmuCell in a research report on Thursday, July 2nd. Wall Street Zen raised shares of ImmuCell to a “strong-buy” rating in a report on Saturday, June 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.